|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Brett_P._Monia
|
|
gptkbp:collaboratesWith
|
gptkb:Biogen
gptkb:AstraZeneca
gptkb:Novartis
gptkb:Roche
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
RNA-targeted therapeutics
|
|
gptkbp:formerName
|
gptkb:Isis_Pharmaceuticals
|
|
gptkbp:foundedYear
|
1989
|
|
gptkbp:founder
|
gptkb:Stanley_T._Crooke
|
|
gptkbp:headquartersLocation
|
gptkb:Carlsbad,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ionis Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:Spinraza
gptkb:Tegsedi
gptkb:Waylivra
|
|
gptkbp:numberOfEmployees
|
over 800
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:publiclyTraded
|
gptkb:NASDAQ:_IONS
|
|
gptkbp:researchInterest
|
cardiovascular diseases
genetic diseases
rare diseases
neurological diseases
|
|
gptkbp:specializesIn
|
antisense oligonucleotide drugs
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:IONS
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.ionispharma.com/
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
5
|